Hello again – now a note about day 2 at the IAPO GPC 2016!
(International Alliance of Patients Organisations) Global Patients Conference 2016)
Sunday morning was devoted to UHC (Universal Health Coverage).  We had two presenters, from the WHO (World Health Organisation), Nittita Prasopa-Plaizier and Mario Ottigilo.    UHC is a global project with the goals :
  • health service coverage;
  • financial risk protection; and 
  • equity or coverage for the entire population.
I believe it was launched in 2008, and has an objective of being implemented by 2030!
You can learn more about it here: http://www.who.int/mediacentre/factsheets/fs395/en/
Nittita Prasopa-Plaizier, WHO, said there was a role for patient organisations in the UHC.  The role of ensuring that people understand their own health care system.  She also talked a lot about putting “the care back into health care” and beginning with the people.  She felt compassion is needed on both sides: Patients prepared, and Doctors attentive. As “Compassionate Care” in UK.
She said that the WHO does not work with patient organisations, but that was where IAPO came in.  IAPO is the go-between for WHO and organisations. 
Mario Ottigilo, WHO, talked about the roles of pharmaceutical companies and the private sector in health care.  There is a place for partnerships with private and pharmas for UHC.  Private companies can support  the UHC through training of healthcare professionals, capacity-building, and awareness campaigns.
Kawaldip Sehmi (IAPOvoice CEO) told us about his grandmother, who was known for tolerating someone until the next wedding party, when she would seek her very public revenge!  He told us to, “Speak up! You have the ability to embarrass the government at the wedding.  Embarrass them into listening to us!” 
Then there was a panel on the different approaches to innovation to health care.
Robert Johnstone, IAPO board member (and now an EPF board member), presented a patient’s view of the NHS (National Health Service in the UK). He talked about the great affection people have for the NHS in the UK, “we love it, especially interaction with doctors”.  NHS is a health system where care and medicine are free at delivery,  but Robert Johnstone said that too little money and effort, only 4% of the budget, is spent on prevention.  He continued, “”The NHS has become a fear-based system whereby ‘we have to treat you, just in case’ .”
Joshua Wamboga, Uganda Network of AIDS Service Organisations, talked about how Rwanda brought global health care just years after genocide.  
We then had two breakout sessions. 
For the first one, I attended the session, “Patient involvement in research: innovation in the drug development and access pathway”, chaired by Antonio Ciaglio, IAPO.
Antonio said in his opening words that patients need to be at the center of research and involved from the start.
Alison Lightbourne, IAPO, says that no matter what everyone says about patients being involved in research, patients are still at the “kids” table.  It will take work to get to more acceptance and involvement of patients.  We all want better drugs coming to market, so we have to work on ensuring that.  There are two projects at the moment that should help that, from IMI: Protect Project and the GetReal Project.
The Protect Project, The goal of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe, using new tools and methods that are profoundly patient-centric. http://www.imi-protect.eu/objectives.shtml
The GetReal Project, aims to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process. Aim is to try and get “real world” info from patients in order to best tackle challenges.   https://www.imi-getreal.eu
IAPO believes that patients have unique needs, and they want to understand what matters to patients most. 
Jane Meijlink International Painful Bladder association, gave such an eye-opening presentation on the role patients can have in standardising terminology and definitions.  “Healthcare is a chain with multiple links and standardisation of terminology and definitions can have an impact on every link in the chain and therefore a major impact on the patients, the patient’s healthcare and ultimately the patient’s whole family.” 
Ricardo C Santiago, Health Insight in Brazil, gave a really fascinating presentation about a maternal health project, EUSAUDE, that includes health analysis. What is really special about this program, is they collect all the data and provide it to do valuable Maternal health analysis in Brazil, which has had an positive impact on maternal health are in Brazil.
–> Dr Santiago is a very good person to follow and to talk to about health data collection and data ownership, which was a recurring topic at this conference.
Kate Hallet of Quintiles, outlined their work.  She said she has been passionate about her work since started working on patient-centric trials in 2005 with lupus Europe! 
She said that Quintiles is creating an easy to search on platform for patients to find clinical trials.  It’s not live yet, but is supposed to be going live soon.  It provoked quite a bit of interest as the www.cinicaltrials.gov website is hard to decipher for a normal person.
There were comments and questions about two projects that IAPO is involved in: IMI, Innovative Medical Initiative (“Europe’s largest Public/private initiative”), aiming to speed up the time to market for new drugs; and PFMD, Patient Focused Development Coalition, which was launched Oct 2015. 
There was a comment that any patient going into the clinical research and/or trials has a very steep learning curve!  And it’s been that way for at least 25 years.  However, the GetReal project and Eupati should help.
Another comment was about the ownership of data being really one of the very key issues that should be addressed very quickly, we are already behind!  There is hope about sharing data and doing data analysis to be had from Big Data technology but we are far from the objective.
The second breakout session was small group networking, and the topic was defined by the attendees.  Our group ended up being the largest, on, “How do we create and sustain strong and capable patients’ organisations;”
After much discussion, the three point plan to ensure a healthy organisation was: 
  1. Have a clear strategic plan, which includes
    1. Shared vision
    2. Shared values
    3. Succession plan, (and make sure you transfer the knowledge! “As soon as you know something, share it with someone in the group.”)
  2. Human Resource (volunteers) Management is essential, with 
    1. Clear, ethical rules
    2. Recognition (say thanks)
  3. Communication
    1. Of strategic plan and vision
We also told IAPO and EPF that we need training and help, and perhaps they can develop a course.   That’s when Camille Bullot of the EPF told us about the upcoming training on “Transparency & Ethics”, and another one: 2016 EPF Regional Advocay Seminar: “Getting the patients’ message across to the national and European levels”.  Have a look here: http://www.eu-patient.eu/Events/
The final plenary concerned different approaches to patient involvement and access.
Penney Cowen, American Chronic Pain Association, showed us the new pain scales they have created and are trying to get accepted by all hospitals in the US. IN fact they have created many different tools for pain and other medical situations. Such good work, and so obvious it seemed strange that their scales hadn’t already been adopted!  https://theacpa.org/Communication-Tools
Victoria Pinkney- Atikinson, Patient Health Alliance of Non governmental Organisations, gave  a very inspiring speech about work that is being done in South Africa.  Very much of a “think global, act local” advocate, and a woman who believes we need to speak up, shout out, about what patients need.  “We patients are too moderate. We need to get active! To unzip our mouths!”  And “Patient groups need to be Watchdogs, not Lapdogs! ” 
Sylvie St-Laurent, Pfizer, spoke about the RA specific platforms.  Apparently they are really looking at involving patients pre-clinical trials and are actively training patients. 
We had the group photo and then the gala dinner for the end of day 2!

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

💜 We've taken part in the EULAR PARE Conference 2026 in Brussels! And what an interesting opportunity to discuss the future of AI in healthcare!

🌍 Bringing together more than 100 delegates and speakers from across Europe and beyond, the conference explored some of the most important questions surrounding artificial intelligence in rheumatology and patient advocacy.

From the opportunities and risks of AI to health inequalities, accessibility and European health policy, the discussions highlighted why patient perspectives must be part of the conversation.

🤩 We were particularly proud to see Jeanette Andersen, Chair of the Lupus Europe Board, sharing our experience with #LupusGPT in her presentation, “AI as a Partner in Care: Empowering the RMD Community with Information”.

💡 Jeanette explained how #LupusGPT was developed with patients and clinicians to offer free, multilingual access to reliable lupus information based on validated sources.

She also introduced #EasyLupus, which provides the same trusted information in simpler language, highlighting why accessibility must be considered when developing AI tools.

But one of the most important messages from her presentation went beyond technology.

💜 Patient organisations have much more to contribute to AI than simply using tools developed by others.

As Jeanette highlighted, patient organisations bring lived experience, knowledge of unmet needs, trusted information and an understanding of the barriers people face when accessing health information.

Technology alone cannot tell us what patients really need or what makes a tool genuinely useful.

Patients and patient organisations should not simply be users of AI. They should help shape its development.

👏 A big thank you to EULAR PARE for bringing together so many different perspectives and creating space for meaningful discussions about the future of healthcare and patient involvement!
...

💜 Weve taken part

🦋 One of the greatest strengths of patient organisations is the support, understanding and sense of community they offer to people living with lupus. 💜

🇧🇬 A great example comes from Организация на пациентите с ревматологични заболявания, who shared their psychological support initiative at the #LupusConvention!

💜 Launched in December 2025, this pilot project provides a safe and supportive space where participants can share their experiences and discuss the challenges of living with lupus, from fatigue and anxiety to relationships and everyday life.

👥 Led by a clinical psychologist, the group currently brings together six women. The project is expected to run until December 2026, while the organisation explores funding opportunities to continue and expand the initiative.

Thank you to our Bulgarian colleagues for sharing their experience, and congratulations on the amazing job you are doing! ❤️

🌍 This is just one example of the valuable work patient organisations are doing across Europe, often responding to needs that go beyond medical care. We'll share more in the coming days!

💜 Are you living with lupus? You don't have to navigate everything alone! Your national lupus organisation may offer information, support, activities and opportunities to connect with others who understand your experiences.

🔗 Find your national lupus organisation and get in touch:
lupus-europe.org/lupus-members/
...

Image attachment
Image attachment

💜 Young people living with lupus are not only the future of patient advocacy. Their voices matter today!

On 23 and 24 October, LUPUS EUROPE was delighted to be represented at the first 𝗘𝗣𝗙 𝗬𝗼𝘂𝘁𝗵 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟲 in Brussels by Ana Rita Vieira, from the LUPUS EUROPE Youth Group, and Lena Koskina, LUPUS EUROPE's Youth Group Coordinator.

🌍 Organised by European Patients' Forum and its EPF Youth Group, the Congress brought together young patient advocates from across Europe to explore the challenges facing young people living with chronic conditions, from economic uncertainty and climate change to the barriers they encounter when trying to influence healthcare decisions.

🌟 One particularly important question ran through the discussions: 𝗵𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗺𝗼𝘃𝗲 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝗶𝗺𝗽𝗹𝘆 𝗴𝗶𝘃𝗶𝗻𝗴 𝘆𝗼𝘂𝗻𝗴 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮 𝘀𝗲𝗮𝘁 𝗮𝘁 𝘁𝗵𝗲 𝘁𝗮𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗲𝘆 𝗵𝗮𝘃𝗲 𝗮 𝗿𝗲𝗮𝗹 𝘀𝗮𝘆 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗯𝗲𝗶𝗻𝗴 𝗺𝗮𝗱𝗲❓

The conversations also highlighted something easily overlooked: 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝘀 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗮𝗻 𝗶𝗻𝘃𝗶𝘁𝗮𝘁𝗶𝗼𝗻. Young people living with chronic conditions are often balancing their health with education, employment and financial pressures. Advocacy opportunities need to recognise those realities, and not be accessible only to those who can afford the time and resources to participate.

🦋 At LUPUS EUROPE, supporting the Youth Group means actively helping create those opportunities, connecting young advocates with others across Europe and ensuring their perspectives can meaningfully contribute to the work we do.

Young people living with lupus are already advocates, bringing their experiences, ideas and knowledge into conversations that matter.

💜 Thank you to European Patients' Forum and its EPF Youth Group for bringing everyone together, and to Rita and Lena for representing LUPUS EUROPE at this important Congress!
...

💜 Young people li

🔊 Hot off the press!

💜 Treatment adherence is important, complex and multifactorial.

But understanding the importance of treatment adherence is not the same as knowing how to support it in everyday clinical practice.

That’s why, in 2020, EULAR published its Points to Consider for the prevention, screening, assessment and management of nonadherence to treatment in people with rheumatic and musculoskeletal diseases.

But having recommendations is only the first step. How can we ensure they become part of everyday clinical practice?

🤩 An interesting new viewpoint published in EULAR Rheumatology Open, co-authored by Jeanette Andersen, Chair of the Lupus Europe Board, now explores the challenges of putting these recommendations into routine rheumatology care.

The article highlights that nonadherence is not simply a matter of individual patient behaviour. Concerns about treatment, practical difficulties, access to medication, socioeconomic circumstances and communication with healthcare professionals can all play a role.

The authors highlight five key priorities for putting adherence support into routine rheumatology practice:

🔹 Assessment: Identifying adherence behaviours and the barriers behind them.
🔹 Monitoring: Reassessing adherence over time, as it may change throughout the disease course.
🔹 Shared decision-making: Discussing patients’ preferences, expectations and concerns through non-judgemental communication.
🔹 Multidisciplinary care: Involving the wider healthcare team according to individual needs.
🔹 Training: Making adherence support part of rheumatology education and professional development.

💜 The challenge is not the lack of recommendations, but making adherence assessment and support a routine part of rheumatology care.

📖 Read the open-access viewpoint: doi.org/10.1016/j.ero.2026.100261
...

Image attachment
Image attachment
Image attachment
Image attachment
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send